In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed the day trading at $3.25 up 1.72% from the previous closing price of $3.19. In other words, the price has increased by $1.72 from its previous closing price. On the day, 0.51 million shares were traded. XFOR stock price reached its highest trading level at $3.32 during the session, while it also had its lowest trading level at $3.05.
Ratios:
For a better understanding of XFOR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.48 and its Current Ratio is at 5.65. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 1.24.
Upgrades & Downgrades
In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 23 ’25 when Craig Adam R bought 86,206 shares for $2.90 per share. The transaction valued at 249,997 led to the insider holds 376,087 shares of the business.
Baldry Mark bought 1,032 shares of XFOR for $2,561 on May 16 ’25. The Chief Commercial Officer now owns 25,337 shares after completing the transaction at $2.48 per share. On Jan 24 ’25, another insider, Ragan Paula, who serves as the President and CEO of the company, sold 76,473 shares for $0.45 each. As a result, the insider received 34,719 and left with 1,087,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 284169248 and an Enterprise Value of 239332240. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.36 while its Price-to-Book (P/B) ratio in mrq is 1.33. Its current Enterprise Value per Revenue stands at 7.044 whereas that against EBITDA is -2.648.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.44, which has changed by -0.7262211 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $26.83, while it has fallen to a 52-week low of $1.35. The 50-Day Moving Average of the stock is -7.10%, while the 200-Day Moving Average is calculated to be -25.97%.
Shares Statistics:
Over the past 3-months, XFOR traded about 882.04K shares per day on average, while over the past 10 days, XFOR traded about 591570 shares per day. A total of 87.44M shares are outstanding, with a floating share count of 78.31M. Insiders hold about 10.44% of the company’s shares, while institutions hold 32.31% stake in the company. Shares short for XFOR as of 1763078400 were 1942100 with a Short Ratio of 2.20, compared to 1760486400 on 1785248. Therefore, it implies a Short% of Shares Outstanding of 1942100 and a Short% of Float of 2.22.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of X4 Pharmaceuticals Inc (XFOR) in the stock market.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.25 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$2.23 and -$3.1 for the fiscal current year, implying an average EPS of -$2.53. EPS for the following year is -$1.2, with 3.0 analysts recommending between -$1.05 and -$1.5.
Revenue Estimates
4 analysts predict $1.99M in revenue for. The current quarter. It ranges from a high estimate of $2.52M to a low estimate of $1.6M. As of. The current estimate, X4 Pharmaceuticals Inc’s year-ago sales were $1.43MFor the next quarter, 4 analysts are estimating revenue of $2.6M. There is a high estimate of $3.3M for the next quarter, whereas the lowest estimate is $1.9M.
A total of 4 analysts have provided revenue estimates for XFOR’s current fiscal year. The highest revenue estimate was $35.07M, while the lowest revenue estimate was $34.1M, resulting in an average revenue estimate of $34.52M. In the same quarter a year ago, actual revenue was $2.56MBased on 4 analysts’ estimates, the company’s revenue will be $13.51M in the next fiscal year. The high estimate is $22.71M and the low estimate is $6.3M.
